The senolytic peptide FOXO4-DRI selectively eliminates brain senescent cells by disrupting the FOXO4-p53 protein complex, demonstrating remarkable therapeutic potential in mammalian aging models. Treatment restored cerebral blood flow, repaired blood-brain barrier integrity, reversed hippocampal atrophy, and enhanced cognitive performance while clearing both amyloid-β plaques and pathological tau proteins in Alzheimer's disease models. This represents a potentially paradigm-shifting approach to brain aging, as senescent cells have emerged as key drivers of neuroinflammation and cognitive decline. The strategy bypasses traditional symptomatic treatments by addressing fundamental cellular aging mechanisms. Early human trials with related compounds like high-dose fisetin show promising cognitive improvements, though the leap from animal models to human application remains substantial. The specificity of FOXO4-DRI for senescent cells while sparing healthy tissue addresses a critical challenge in anti-aging interventions. However, questions remain about optimal dosing, treatment duration, and long-term safety in humans. If translatable, this senolytic approach could revolutionize how we address age-related cognitive decline, moving beyond management to potential reversal of brain aging processes.